B. Riley Financial Inc. bought a new stake in shares of Osiris Therapeutics, Inc. (OTCMKTS:OSIR) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 52,110 shares of the biotechnology company’s stock, valued at approximately $578,000. B. Riley Financial Inc. owned approximately 0.15% of Osiris Therapeutics at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of OSIR. CAPROCK Group Inc. purchased a new position in shares of Osiris Therapeutics during the 3rd quarter valued at approximately $111,000. Deltec Asset Management LLC purchased a new stake in Osiris Therapeutics in the 3rd quarter worth $555,000. Gamco Investors INC. ET AL purchased a new stake in Osiris Therapeutics in the 3rd quarter worth $777,000. Gabelli Funds LLC purchased a new stake in Osiris Therapeutics in the 3rd quarter worth $5,110,000. Finally, SG Americas Securities LLC purchased a new stake in Osiris Therapeutics in the 3rd quarter worth $141,000. 0.28% of the stock is owned by hedge funds and other institutional investors.
Separately, TheStreet raised shares of Osiris Therapeutics from a “d+” rating to a “c-” rating in a report on Wednesday, October 3rd.
Shares of OTCMKTS OSIR opened at $12.56 on Tuesday. Osiris Therapeutics, Inc. has a one year low of $5.62 and a one year high of $14.35.
Osiris Therapeutics (OTCMKTS:OSIR) last issued its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported $0.11 EPS for the quarter. The company had revenue of $36.49 million during the quarter.
ILLEGAL ACTIVITY WARNING: “B. Riley Financial Inc. Takes $578,000 Position in Osiris Therapeutics, Inc. (OSIR)” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/12/18/b-riley-financial-inc-takes-578000-position-in-osiris-therapeutics-inc-osir.html.
Osiris Therapeutics Company Profile
Osiris Therapeutics, Inc researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints.
See Also: What is systematic risk?
Want to see what other hedge funds are holding OSIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Osiris Therapeutics, Inc. (OTCMKTS:OSIR).
Receive News & Ratings for Osiris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.